Alprostadil (MUSE, Caverject, Edex): Complete Guide to Dosing, Efficacy, and How It Compares to PDE5 Inhibitors

What Is Alprostadil and How Does It Work?

Alprostadil is a synthetic form of prostaglandin E1 (PGE1). It binds EP2 and EP3 receptors on cavernosal smooth-muscle cells, raises intracellular cyclic AMP, and relaxes smooth muscle directly. Blood flows in, the corpora cavernosa expand, and an erection results, all without requiring sexual stimulation to trigger the nitric-oxide cascade that PDE5 inhibitors depend on. 1

That mechanism matters clinically. Men with severe cavernous nerve damage, the most common consequence of radical prostatectomy, often cannot generate enough nitric oxide to benefit from sildenafil or tadalafil. Alprostadil bypasses that bottleneck entirely. A 2009 systematic review in the British Journal of Urology International confirmed that intracavernosal alprostadil produced erections sufficient for intercourse in 70 to 80% of post-prostatectomy patients who had not responded to oral agents. 2

The FDA approved Caverject (Pfizer) in 1995 and MUSE (Meda Pharmaceuticals) in 1996. Edex (Schwarz Pharma) received approval as a second injectable formulation. All three carry the same active molecule; they differ in delivery vehicle, concentration, and reconstitution method. 3

MUSE (Medicated Urethral System for Erection): Dosing and Efficacy

MUSE delivers alprostadil as a tiny pellet inserted 3.2 cm into the urethra using a single-use plastic applicator. The pellet dissolves in urethral secretions, and the drug absorbs through the urethral mucosa into the corpus spongiosum and then into the corpora cavernosa. Onset is typically 5 to 10 minutes. 4

Doses available are 125 mcg, 250 mcg, 500 mcg, and 1 to 000 mcg. The prescribing convention is to start at 250 mcg, titrate upward in a supervised in-office setting, and then dispense the identified effective dose for home use. 5

The key MUSE trial (Padma-Nathan et al., 1997, N=1,511) found that 64.9% of men who received the active suppository achieved at least one erection sufficient for intercourse at home, versus 18.6% of placebo recipients (P<0.001). Among men who responded in-office, 66% sustained the response across home use attempts. 6

Real-world retention is lower. A separate observational cohort showed that roughly 50% of MUSE users discontinue within 12 months, most citing penile pain (reported in 32% of active-drug users in the key trial) and insertion discomfort. Urethral burning is dose-dependent and tends to improve after the first few uses. 7

Urethral strictures, penile anatomical abnormalities, or conditions causing hypersensitivity to PGE1 are contraindications. Because the drug may be absorbed systemically through vaginal mucosa, condom use is recommended when a pregnant partner is present. 5

Caverject and Edex (Intracavernosal Injection): Dosing and Efficacy

Caverject and Edex are injected directly into the lateral shaft of the corpus cavernosum using a 27- to 30-gauge needle. The injection site is the 3 o'clock or 9 o'clock position along the proximal third of the penile shaft. Onset is 5 to 20 minutes, and duration averages 30 to 60 minutes. 8

Caverject is supplied as a lyophilized powder (5, 10, 20, or 40 mcg per vial) that is reconstituted with bacteriostatic sodium chloride before injection. Caverject Impulse is a prefilled dual-chamber syringe that eliminates manual mixing. Edex comes as 10, 20, or 40 mcg powder-vials with an identical reconstitution protocol. Starting doses are typically 1.25 to 2.5 mcg in neurogenic ED and 2.5 to 5 mcg in vasculogenic ED, with in-office titration until a 60-minute erection is achieved. Maximum recommended dose is 40 mcg per injection. 9

Efficacy data are strong. The Caverject registration trial (Linet and Ogrinc, 1996, N=683 randomized) reported a 94% in-office erection rate versus 15% for placebo. At home, 87% of men who achieved an in-office response reported successful intercourse on at least 50% of attempts. 8

A 2020 Cochrane review of intracavernosal vasoactive agents (including alprostadil monotherapy, N over 3,500 across trials) rated the evidence for penile rigidity sufficient for penetration as high-quality, with a mean success rate per attempt of 72% (95% CI: 67 to 77%). 10

The most common adverse effect is penile pain at the injection site, occurring in approximately 11% of men in clinical trials. Penile fibrosis (Peyronie's-like plaques at the injection site) may develop with long-term use; the published incidence in studies extending beyond 12 months is 2 to 4%. Priapism, an erection lasting more than 4 hours, occurs in roughly 1% of injections and requires prompt medical intervention to prevent permanent ischemic damage. 9

Frequency of use should not exceed one injection per 24 hours or more than three injections per week.

Head-to-Head: Alprostadil vs. PDE5 Inhibitors

Sildenafil (Viagra)

Sildenafil, the first oral PDE5 inhibitor, was approved by the FDA in March 1998. The registration program (Goldstein et al., 1998, NEJM, N=861) showed a mean improvement of 5.0 points on the International Index of Erectile Function (IIEF) erectile-function domain versus 1.0 point for placebo at 100 mg (P<0.001). The drug is taken 30 to 60 minutes before intercourse; a high-fat meal delays absorption by up to 60 minutes. Duration of effect is approximately 4 to 6 hours. 11

Sildenafil depends entirely on endogenous nitric-oxide release triggered by sexual stimulation. Men with cavernous nerve damage, testosterone deficiency below approximately 200 ng/dL, or severe arterial insufficiency often see limited benefit. A 2002 prospective study (N=91) found that only 35% of men with complete cavernous nerve injury achieved IIEF scores in the non-ED range on sildenafil 100 mg. 12

Common side effects include headache (15%), flushing (10%), dyspepsia (7%), and transient visual changes including blue-tinge (3%). Sildenafil is absolutely contraindicated with organic nitrates due to severe hypotension risk. 11

Generic sildenafil has been available in the United States since 2017, reducing cost substantially, GoodRx pricing for 6 tablets of sildenafil 50 mg runs approximately $25, $35, compared to $400, $500 for branded Viagra. 13

Tadalafil (Cialis)

Tadalafil's 36-hour duration separates it from every other oral ED drug. The molecule has a longer half-life (17.5 hours versus sildenafil's 4 hours) and is not significantly affected by food. The FDA approved tadalafil (Eli Lilly) in November 2003. 14

The IIEF data from registration trials showed that tadalafil 20 mg improved the erectile-function domain score by a mean of 8.6 points versus 1.8 points for placebo (P<0.001) across men with mixed-etiology ED. 15

Two dosing strategies exist. As-needed dosing uses 5 to 20 mg taken before anticipated activity. Daily low-dose dosing uses 2.5 to 5 mg taken at the same time each day, which normalizes intracavernosal PDE5 inhibition continuously and avoids the need to plan around a dose window. A 2014 randomized trial (N=186) found that daily tadalafil 5 mg for 9 months after nerve-sparing radical prostatectomy produced significantly better erection recovery than on-demand dosing (52% vs. 26% success rate at 9 months, P<0.05). 16

Tadalafil also carries FDA approval for benign prostatic hyperplasia (BPH) at 5 mg daily, offering a single drug for men with both conditions.

Vardenafil (Levitra, Staxyn)

Vardenafil was approved in August 2003. Its half-life is approximately 4 to 5 hours, onset is 25 to 60 minutes, and standard doses are 5, 10, and 20 mg. Staxyn is an orally disintegrating tablet (10 mg) that dissolves on the tongue without water. 17

Registration-trial data (Goldstein et al., 2003, IIEF, N=805) showed that vardenafil 20 mg improved the erectile-function domain by 8.0 points versus 1.9 for placebo (P<0.001). A subgroup analysis of men with type 2 diabetes (N=452) found that 57% achieved normal IIEF-EF scores on vardenafil 10 mg or 20 mg versus 10% on placebo, a population historically resistant to oral ED therapy. 18

Vardenafil has a greater selectivity for PDE5 over PDE6 (the retinal isoform) than sildenafil does, which may explain its lower rate of visual disturbances. A high-fat meal reduces peak concentration by approximately 18 to 50%. 17

Avanafil (Stendra)

Avanafil received FDA approval in April 2012 and is the newest oral PDE5 inhibitor. Its defining feature is rapid onset: 15 to 30 minutes. A 2012 registration trial (Goldstein et al., N=646) showed that 67% of men taking avanafil 200 mg achieved successful intercourse within 15 minutes of dosing versus 27% on placebo (P<0.001). 19

Half-life is approximately 5 hours. Doses are 50 mg, 100 mg, and 200 mg. Avanafil shows 100-fold selectivity for PDE5 over PDE6, which correlates with a very low rate of visual side effects (<1% in trials). Food does not meaningfully affect absorption. 19

Avanafil is not yet available as a generic, so cost is higher, typically $35, $55 per tablet at retail without insurance. 20

When Alprostadil Is the Right Choice Over Oral Agents

Four clinical scenarios favor alprostadil over PDE5 inhibitors.

Complete cavernous nerve damage. After non-nerve-sparing radical prostatectomy, intracavernosal alprostadil (20 to 40 mcg) may be the only pharmacotherapy capable of producing a functional erection. Penile rehabilitation protocols using tri-weekly injections began within 6 weeks of surgery have shown preservation of smooth-muscle architecture in prospective studies. 21

Nitrate co-therapy. Men taking isosorbide mononitrate or sublingual nitroglycerin for angina cannot take any PDE5 inhibitor safely. Alprostadil carries no interaction with nitrates because it does not inhibit PDE5. 9

PDE5 inhibitor non-response. The American Urological Association (AUA) 2018 ED guideline states: "Intracavernosal vasoactive drug injection is recommended as second-line therapy in patients who do not respond to or cannot use PDE5 inhibitors." 22

Diagnostic use. A 10 to 20 mcg intracavernosal alprostadil injection is the standard pharmacological challenge used during penile Doppler ultrasonography to assess arterial inflow and venous occlusion. PDE5 inhibitors cannot reliably achieve the full intracavernosal pressure needed for accurate Doppler interpretation. 23

Combination Therapy: Alprostadil Plus Oral PDE5 Inhibitors

Some men respond inadequately to either treatment alone but well to both together. A randomized crossover study (McMahon et al., 2004, N=40) found that sildenafil 50 mg taken 30 minutes before a subtherapeutic MUSE dose (500 mcg) produced significantly higher IIEF scores than either agent alone (mean IIEF-EF 22.4 combined vs. 16.8 MUSE alone vs. 17.1 sildenafil alone, P<0.01). 24

The combination requires careful titration. Both drugs lower systemic blood pressure; the combination may produce more pronounced hypotension, particularly in men also on antihypertensives or alpha-blockers. Starting with reduced doses of each agent and titrating under clinician supervision is the standard approach. 24

Safety, Monitoring, and Practical Training

Before dispensing Caverject or Edex for home use, clinicians should walk patients through injection technique in office, confirm a satisfactory erection at the dispensed dose (lasting no more than 60 minutes), and provide written instructions for managing priapism. The AUA guideline specifies that any erection exceeding 4 hours requires emergency evaluation; men should be instructed to go to an emergency department after failing home interventions (application of an ice pack, physical exercise). 22

Long-term safety data from the European Alprostadil Study Group (N=848, follow-up to 3 years) showed that fibrosis at the injection site occurred in 2.6% of men, and the rate did not increase substantially beyond the first year of use. Penile pain declined over time as men gained experience with injection technique. 25

For MUSE, practitioners should counsel patients to urinate before insertion (urethral moisture aids pellet dissolution), remain standing or walking during the 10-minute absorption window (gravity aids corporal distribution), and avoid vigorous penile massage, which may redistribute drug away from the corpora. 5

The AUA 2018 guideline, authored by the panel chaired by Arthur Burnett, M.D., states that "clinicians should discuss the benefits and risks of all available ED therapies so that patients and their partners can make an informed decision." That means giving alprostadil parity in the conversation with oral agents, not presenting it only as a last resort. 22

Alprostadil Cost and Access

Caverject Impulse (20 mcg, 2 syringes) retails at approximately $260, $320 without insurance. Edex (20 mcg, 6 vials) runs approximately $200, $270. Neither has an FDA-approved generic equivalent as of mid-2025, though compounded alprostadil (505B2 compounders) is available through select telehealth pharmacies at lower cost. The FDA has not found the compounded versions bioequivalent, so clinical outcomes may vary. 26

MUSE (1 to 000 mcg, 6 pellets) retails near $500, $600 without insurance. Given that MUSE has a lower overall response rate than injection therapy, cost-effectiveness analysis generally favors intracavernosal alprostadil when a patient requires a non-oral option. 6

Men with Medicare Part D may find alprostadil covered under durable medical equipment (DME) guidelines if injectable, though coverage varies by plan. Private insurance coverage for all ED drugs remains inconsistent; most Affordable Care Act benchmark plans exclude ED medication as a benefit class. 27

Comparison Table: Alprostadil vs. PDE5 Inhibitors at a Glance

| Drug | Route | Onset | Duration | Needs Sexual Stimulation | Works Post-Prostatectomy | |---|---|---|---|---|---| | Alprostadil injection (Caverject/Edex) | Intracavernosal | 5 to 20 min | 30 to 60 min | No | Yes (70 to 80%) | | Alprostadil MUSE | Intraurethral | 5 to 10 min | 30 to 60 min | No | Partial (30 to 65%) | | Sildenafil (Viagra) | Oral | 30 to 60 min | 4 to 6 hr | Yes | Limited | | Tadalafil (Cialis) | Oral | 30 to 120 min | Up to 36 hr | Yes | Limited | | Vardenafil (Levitra/Staxyn) | Oral | 25 to 60 min | 4 to 5 hr | Yes | Limited | | Avanafil (Stendra) | Oral | 15 to 30 min | 5 to 6 hr | Yes | Limited |